Furthermore, early-stage trials of combination therapy with lenvatinib plus the anti–programmed death 1 (PD-1) antibodies pembrolizumab or nivolumab have similarly reported high ORRs of 40.3% and 54.2%, respectively, in patients with HCC [8, 9]. Here, RPL17 is linked to hepatocellular carcinoma.